Cogent Biosciences, Inc. COGT Business Segments
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Operating Income by Business | ||||
| Depreciation Expense | $2.56M+4.6% | $2.45M+8.3% | $2.26M+169% | |
| Early Stage Preclinical And Discovery Programs | $40.11M+42.5% | $28.14M+46.8% | $19.17M+48.0% | |
| Latestage Development | $120.06M-0.7% | $120.86M+41.4% | $85.48M+39.5% | |
| Other Operational Infrastructure And Advisory Support | $40.44M+50.4% | $26.89M+16.8% | $23.01M+6.5% | |
| Research And Development Personnel Related | $63.88M+35.8% | $47.05M+23.1% | $38.21M+44.6% | |
| Research And Development Software Facilities And Other Strategic Support | $20.24M+80.7% | $11.2M+19.5% | $9.37M+47.0% | |
| Stock-Based Compensation Expense | $46.08M+16.0% | $39.74M+29.8% | $30.62M+66.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Cogent Biosciences, Inc. break its business down?
- Cogent Biosciences, Inc. (COGT) reports operating income by business across 7 parts — Depreciation Expense, Early Stage Preclinical And Discovery Programs, Latestage Development, Other Operational Infrastructure And Advisory Support and Research And Development Personnel Related. Each is extracted from the segment footnotes and tracked over time.
- Where does Cogent Biosciences, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Cogent Biosciences, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
